PRINCIPLES OF MONITORING OF ADVERSE EVENTS AFTER VACCINATION IN RUSSIAN FEDERATION AND THE WORLD

Cover Page


Cite item

Full Text

Abstract

Difference in terminology accepted in our and foreign countries for designating disease of post-vaccination period is shown. Analysis of the existing regulating documents in Russian Federation regarding registration of adverse events in post-vaccination period and system of registration accepted in many countries of the world and recommended by WHO is presented. In Russian Federation in accordance with the documents of the Federal Service of Surveillance for Protection of Consumers Rights and Human Welfare only certain conditions (post-vaccinal complications) are subject to registration. In accordance with WHO recommendations all adverse events taking place 1 month after the vaccination must be registered. Summarization of these data allows to detect interconnection between these conditions and vaccination or prove the lack thereof.

About the authors

E. P. Nacharova

Research Institute of Childrens’ Infections

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

S. M. Kharit

Research Institute of Childrens’ Infections

Email: noemail@neicon.ru
Russian Federation

Yu. V. Lobzin

Research Institute of Childrens’ Infections

Email: noemail@neicon.ru
Russian Federation

N. I. Briko

Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

References

  1. Григорьев К. И. Корь: что впереди - ликвидация инфекции или эпидемия? Медицинская сестра. 2012, 7:9-13.
  2. Лакоткина Е.А., Харит С.М., Черняева Т.В. и др. Поствакцинальные осложнения (клиника, диагностика, лечение, профилактика): Пособие для практического врача. М., 2004.
  3. Лыткина И.Н., Заволжских А.М. Современные особенности эпидемиологии коревой инфекции в условиях мегаполиса. Педиатрия. 2013, 1: 15-17.
  4. Львова И.И., Фельдблюм И.В., Корюкина И.П. и др. Мониторинг событий поствакцинального периода. Эпидемиология и инфекционные болезни. 2004, 5: 2-14.
  5. Методические указания МУ 3.3.1.1123-02 3.3.1. Вакцинопрофилактика. Мониторинг поствакцинальных осложнений и их профилактика. Методические указания (утв. Главным государственным санитарным врачом РФ 26.05.2002). http://www.consultant. ru/document/cons_doc_LAW_100503/.
  6. Методические указания МУ 3.3.1879-04. Расследование поствакцинацльных осложнений (утв. главным государственным санитарным врачем РФ 04.03.2004). http://www. hrsa.gov/vaccinecompensation/data/statisticsreport.pdf.
  7. Семенов Б.Ф., Лябис О.И., Михайлова Н.А. Основные этапы развития вакцинологии и вакцинопрофилактики. Вакцины и вакцинация: Национальное руководство. Под ред. В.В. Зверева, Б.Ф. Семенова, Р.М. Хаитова. М., ГЭОТАР-Медиа, 2011, с. 18-25.
  8. Тихонова Н.Т., Герасимова А.Г., Цвиркун О.В. и др. Причины роста заболеваемости корью в России в период элиминации инфекции. Педиатрия. 2013,1: 9-14.
  9. Учайкин В.Ф., Шамшева О.В. Вакцинопрофилактика: настоящее и будущее. М., 2006.
  10. Харит С.М. Вакцинопрофилактика: проблемы и перспективы. Журн. инфектологии. 2009,1 (1): 61-65.
  11. Харит С.М., Черняева Т.В., Лакоткина Е.А. Структура заболеваний поствакцинального периода (анализ наблюдений за 40 лет). Эпидемиология и вакцинопрофилактика. 2010, 2 (51): 64-69.
  12. Ясинский А.А. Законодательные аспекты вакцинопрофилактики. Вакцины и вакцинация: Национальное руководство. Под ред. В.В.Зверева, Б.Ф.Семенова, Р.М.Хаитова. М., ГЭОТАР-Медиа, 2011, с. 826-831.
  13. Ясинский А.А., Михеева И.В. Безопасность иммунизации. Вакцины и вакцинация: Национальное руководство. Под ред. В.В. Зверева, Б.Ф. Семенова, Р.М. Хаитова. М., ГЭОТАР-Медиа, 2011, с. 137-162.
  14. Asatryan A., Pool V., Chen R.T. et al. Live attenuated measles and miumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990 - 2003. Vaccine. 2008, 26 (9): 1166-1172.
  15. Bonhoeffer J., Zumbrunn B., Heininger U. Reporting of vaccine safety data in publications: systematic review. Pharmacoepidemiol. Drug Saf. 2005, 14 (2): 101-106.
  16. Boyd S.D., Jackson K.J. Predicting vaccine responsiveness. Cell. Host. Microbe. 2015, 17 (3): 301-307.
  17. Boyman O., Comte D., Spertini F. Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol. 2014, 10 (10): 612-627.
  18. Cashman R, Moberley S., Dalton C. et al. Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children. Vaccine. 2014, 32 (42): 5503-5508.
  19. Centers for Disease Control and Prevention (CDC). Syncope after vaccination - United States, January 2005-July 2007. MMWR. 2008, 57 (17): 457-460.
  20. Crawford N.W., Clothier H., Hodgson K. et al. Active surveillance for adverse events following immunization. Expert. Rev. Vaccines. 2014, 13 (2): 265-276.
  21. Fine P. Science and society: vaccines and public health. Public Health. 2014, 128 (8): 686-692.
  22. Global Advisory Committee on Vaccine Safety (GACVS); WHO secretariat. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert. Rev. Vaccines. 2009, 8 (6): 705-716.
  23. Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R. Soc. bond. B. Biol Sci. 2014, 369 (1645): 20130433.
  24. Haber P., Iskander J., Walton K. et al. Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety. Pediatrics. 2011, 127 (Suppl. 1): 39-44.
  25. Halsey N.A., Edwards K.M., Dekker C.L. et al. Algorithm to assess causality after individual adverse events following immunizations. Vaccine. 2012, 30 (39): 5791-5798.
  26. Huang Y.L., Moon J., Segal J.B. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014, 37 (8): 581-596.
  27. Jarrett C., Wilson R., O'Leary M. et al. Strategies for addressing vaccine hesitancy - A systematic review. Vaccine. 2015, 33 (34): 4180-4190.
  28. Jones P.G., Cowan G., Gravendyck M. et al. Regulatory requirements for vaccine authorisation. Rev. Sci. Tech. 2007, 26 (2): 379-393.
  29. Lawrence G., Gold M.S., Hill R. et al. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun. Dis. Intell. Q. Rep. 2008, 32 (4): 371-387.
  30. Leca M., Bomet C, Montana M. et al. Meningococcal vaccines: Current state and future outlook. Pathol. Biol. (Paris). 2015, 63 (3): 144-151.
  31. Lee C.J., Lee L.H., Lu C.H. Safety monitoring in vaccine development and immunization. Acta Paediatr. Taiwan. 2006, 47 (1): 7-13.
  32. Leeb A., Regan A.K., Peters I.J. etal. Using automated text messages to monitor adverse events following immunisation in general practice. Med. J. Aust. 2014, 200 (7): 416-418.
  33. Lopalco P.L., Johansen K., Ciancio B. Monitoring and assessing vaccine safety: a European perspective. Expert. Rev. Vaccines. 2010, 9 (4): 371-380.
  34. Maglione M.A., Das L., Raaen L. et al. Safety of vaccines used for routine immunization of U.S. children: a systematic review. Pediatrics. 2014, 134 (2): 325-337.
  35. McNeil M.M., Gee J., Weintraub E.S. et al. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine. 2014, 32 (42): 5390-5398.
  36. Muehlhans S., Richard G., Ali M. et al. Safety reporting in developing country vaccine clinical trials-a systematic review. Vaccine. 2012, 30 (22): 3255-3265.
  37. National Vaccine Injury Compensation Program Data Report - March 1, 2016.
  38. Niu M.T., Ball R., Woo E.J. et al. Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine. 2009, 27 (2): 290-297.
  39. Parez N., Giaquinto C, Du Roure C. et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect. Dis. 2014, 14 (5): 416-425.
  40. Rappuoli R., Pizza M., Del Giudice G. et al. Vaccines, new opportunities for a new society. Proc. Nat. Acad. Sci. USA. 2014, 111 (34), 6: 12288-12293.
  41. Schuster M., Eskola J., Duclos P. et al. Review of vaccine hesitancy: Rationale, remit and methods. Vaccine. 2015, 33 (34): 4157-4160.
  42. ShimabukuroT.T., Nguyen M., Martin D. et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015, pii: S0264-410X( 15)00982-2.
  43. Soriano A., Nesher G., Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol. Res. 2015, 92: 18-22.
  44. Thoon K.C., Soh S.B., Liew W.K. et al. Active surveillance of adverse events following childhood immunization in Singapore. Vaccine. 2014, 32 (39): 5000-5005.
  45. Tozzi A. E., Asturias E.J., Balakrishnan M.R. et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013, 31 (44): 5041-5046.
  46. William S.E., Barlow Ph.D., Robert L. Davis et al. The risk of seizures after receipt of wholecell pertussis or measles, mumps, and rubella vaccine. For the Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group. The New England Journal of Medicine. 2001,345:656-661.
  47. Williams S.E., Klein N.P., Halsey N. et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine. 2011, 29 (40): 6920-6927.
  48. Woo E.J., Wise R.P., Menschik D. et al. Thrombocytopenia after vaccination: case reports to the US vaccine adverse event reporting system, 1990 - 2008. Vaccine. 2011, 29: 1319-1323.
  49. Yaqub O., Castle-Clarke S., Sevdalis N. et al. Attitudes to vaccination: a critical review. Soc. Sci. Med. 2014, 112:1-11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Nacharova E.P., Kharit S.M., Lobzin Y.V., Briko N.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies